Ligand Pharmaceuticals Announces Up to $47M Financing with AvenCell

What Happened
On September 24, 2026, Ligand Pharmaceuticals Incorporated (LGND) announced via Form 8-K (Regulation FD disclosure) that it entered a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR‑T therapies for cancer. The announced transaction provides for up to $47 million in financing. Ligand furnished a press release about the transaction as Exhibit 99.1 to the 8‑K.

Key Details

• Date filed: September 24, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Amount: Financing agreement for up to $47.0 million.
• Counterparty: AvenCell Therapeutics, a clinical‑stage developer of controllable, allogeneic CAR‑T therapies for cancer.
• Disclosure: Press release dated September 24, 2026 was furnished as Exhibit 99.1 to the 8‑K.

Why It Matters
This filing confirms Ligand is committing capital to a clinical‑stage cell therapy company, signaling active deployment of funds into oncology-related partnerships. For investors, the material facts to watch next are the financing terms (equity vs. debt, milestones, warrants, interest, timing) and any subsequent disclosures on accounting treatment or potential revenue/expense impacts. The press release and future filings should provide those specifics.